Multimodality therapy in subclassified stage IIIA–N2 non-small cell lung cancer patients according to the Robinson classification: heterogeneity and management | Zendy

HansStefan Hofmann | Zendy; Jan Braess | Zendy; Susanne Leipelt | Zendy; Michael Allgäuer | Zendy; Monika KlinkhammerSchalke | Zendy; Tamas Szoeke | Zendy; Christian Großer | Zendy; Roman Pfeifer | Zendy; Michael Ried | Zendy

Open Access

Multimodality therapy in subclassified stage IIIA–N2 non-small cell lung cancer patients according to the Robinson classification: heterogeneity and management

Author(s) -

HansStefan Hofmann,

Jan Braess,

Susanne Leipelt,

Michael Allgäuer,

Monika KlinkhammerSchalke,

Tamas Szoeke,

Christian Großer,

Roman Pfeifer,

Michael Ried

Publication year - 2018

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2018.05.203

Subject(s) - medicine , stage (stratigraphy) , lung cancer , multimodality , oncology , linguistics , philosophy , paleontology , biology

Non-small cell lung cancer (NSCLC) with mediastinal lymph node involvement (N2) is a heterogeneous entity. The objective of this analysis is to investigate the results of treatment strategies for N2-positive patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research